Massive Bio Unveils Groundbreaking Oncology/Hematology AI Platform at ASCO 2024: Revolutionizing Oncology/Hematology with AI Driven Personalized Insights for Clinical Trial Accessibility
Published
NEW YORK--(BUSINESS WIRE)--At the forefront of oncological/hematological innovation, Massive Bio, Inc. is set to showcase its pioneering AI technology at the ASCO Annual Meeting 2024, highlighting a major leap in patient and physician engagement in cancer care. The company will unveil its latest advancements in the Massive Bio Deep Learning Clinical Trial Matching System (DLCTMS, aka Synergy-AI), an AI platform designed to transform how cancer clinical trials are accessed and managed globally b
Full Article